Wells Fargo’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-15,384
| Closed | -$2K | – | 7267 |
|
|
2019
Q4 | $2K | Hold |
15,384
| – | – | ﹤0.01% | 6217 |
|
|
2019
Q3 | $2K | Hold |
15,384
| – | – | ﹤0.01% | 6243 |
|
|
2019
Q2 | $2K | Hold |
15,384
| – | – | ﹤0.01% | 6210 |
|
|
2019
Q1 | $3K | Sell |
15,384
-114,678
| -88% | -$25.4K | ﹤0.01% | 5840 |
|
|
2018
Q4 | $91K | Sell |
130,062
-600
| -0.5% | -$670 | ﹤0.01% | 5329 |
|
|
2018
Q3 | $161K | Hold |
130,662
| – | – | ﹤0.01% | 5123 |
|
|
2018
Q2 | $145K | Hold |
130,662
| – | – | ﹤0.01% | 5196 |
|
|
2018
Q1 | $263K | Sell |
130,662
-13,500
| -9% | -$25.3K | ﹤0.01% | 4827 |
|
|
2017
Q4 | $172K | Buy |
144,162
+13,500
| +10% | +$18.4K | ﹤0.01% | 5038 |
|
|
2017
Q3 | $165K | Buy |
130,662
+106,178
| +434% | +$136K | ﹤0.01% | 5019 |
|
|
2017
Q2 | $32K | Sell |
24,484
-21,886
| -47% | -$31.6K | ﹤0.01% | 5524 |
|
|
2017
Q1 | $86K | Buy |
46,370
+23,316
| +101% | +$105K | ﹤0.01% | 5261 |
|
|
2016
Q4 | $119K | Buy |
23,054
+9,709
| +73% | +$51.1K | ﹤0.01% | 5064 |
|
|
2016
Q3 | $74K | Sell |
13,345
-750
| -5% | -$4.28K | ﹤0.01% | 5099 |
|
|
2016
Q2 | $78K | Sell |
14,095
-409
| -3% | -$2.15K | ﹤0.01% | 4971 |
|
|
2016
Q1 | $64K | Buy |
14,504
+308
| +2% | +$1.27K | ﹤0.01% | 5123 |
|
|
2015
Q4 | $85K | Buy |
14,196
+12,255
| +631% | +$83.2K | ﹤0.01% | 5032 |
|
|
2015
Q3 | $15K | Sell |
1,941
-751
| -28% | -$5.82K | ﹤0.01% | 5623 |
|
|
2015
Q2 | $16K | Buy |
2,692
+842
| +46% | +$6.53K | ﹤0.01% | 5680 |
|
|
2015
Q1 | $15K | Sell |
1,850
-5,250
| -74% | -$39.6K | ﹤0.01% | 5495 |
|
|
2014
Q4 | $36K | Sell |
7,100
-500
| -7% | -$2.47K | ﹤0.01% | 5156 |
|
|
2014
Q3 | $39K | Sell |
7,600
-500
| -6% | -$3.23K | ﹤0.01% | 5026 |
|
|
2014
Q2 | $63K | Buy |
8,100
+3,000
| +59% | +$21.2K | ﹤0.01% | 4881 |
|
|
2014
Q1 | $36K | Buy |
+5,100
| New | +$39.8K | ﹤0.01% | 5036 |
|
Wells Fargo's GNMX Position: Q1 2020 in Review
Wells Fargo sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 15,384 shares — an estimated $2K sold.
Wells Fargo first reported a position in GNMX in Q1 2014 and held it in 24 quarters. The position peaked at $263K in Q1 2018. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Wells Fargo reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Wells Fargo sold 15,384 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $2K.
- Wells Fargo first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 24 quarters.
- Wells Fargo's Aevi Genomic Medicine Inc position peaked at $263K in Q1 2018.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Wells Fargo's 13F filing for Q1 2020, filed 14 May 2020.